Cure My Disease

Don't miss your cure!

 Log in / Sign up

Korea launches safety watch on meningitis vaccine MenQuadfi

NCT ID NCT07621653

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 2 times

Summary

This study will monitor the safety of the MenQuadfi vaccine in 706 people aged 6 weeks to 55 years in South Korea. Researchers will track side effects like injection-site reactions and serious adverse events as the vaccine is used in real-world clinics. The goal is to confirm the vaccine's safety profile outside of controlled trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
MenQuadfi (meningococcal groups A, C, Y, W polysaccharide tetanus toxoid conjugate vaccine)
What this could lead to
If successful, this study will confirm that MenQuadfi is safe for routine use in Korea, helping protect against serious meningococcal disease.
What could go wrong
This is an observational safety study, not a test of effectiveness. It may not detect rare side effects due to its size and real-world setting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

meningococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS MENINGOCOCCAL IMMUNIZATION

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Investigational Site Number: 410003

    RECRUITING

    Goyang, 10234, South Korea

  • Investigational Site Number: 410004

    RECRUITING

    Seoul, 06132, South Korea

  • Investigational Site Number: 410005

    RECRUITING

    Seongnam, 13558, South Korea

  • Investigational Site Number: 410006

    RECRUITING

    Iksan, 54639, South Korea

  • Investigational Site Number: 410007

    RECRUITING

    Seoul, 06614, South Korea

  • Investigational Site Number: 410008

    RECRUITING

    Gwangju, 61665, South Korea

  • Investigational Site Number: 410009

    RECRUITING

    Busan, 49408, South Korea

  • Investigational Site Number: 410010

    RECRUITING

    Hanam, 12919, South Korea

  • Investigational Site Number: 410011

    RECRUITING

    Daegu, 41794, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.